BeiGene’s tislelizumab met primary endpoint in Phase 3 trial for unresectable HCC liver cancer
The PD-1 inhibitor tislelizumab “met the primary endpoint of non-inferior overall survival (OS) versus sorafenib” in the global Phase 3 trial as a first-line […]











